

I hereby certify that this correspondence is being deposited with the United States Patent and Trademark Service, with sufficient postage, as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, D.C. 20231
on April 9, 2002

Date of Deposit

David Rozenblat, Reg. No. 47,044

Name of applicant, assignee or
Registered Representative

David Rozenblat

Signature
April 9, 2002

Date of Signature

430
D3
#4
RECEIVED
APR 22 2002
TECHNOLOGY CENTER R3700

Our Case No.: 8465/20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Mogensen et al.

Serial No.: 09/995,237

Filing Date: November 26, 2001

For: INJECTOR DEVICE FOR
PLACING A SUBCUTANEOUS
INFUSION SET

Examiner: To Be Assigned

Group Art Unit No.: 3763

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Second Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:


U.S. PATENT DOCUMENTS		
No.	Date	Name
6,017,328	01/25/01	Fischell et al.

In accordance with 37 C.F.R. § 1.97(g),(h), this Second Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Second Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

Applicant(s) respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,


 David Rozenblat
 Registration No. 47,044
 Attorney for Applicant(s)

BRINKS HOFER GILSON & LIONE
 P.O. Box 10395
 Chicago, IL 60610
 (312) 321-4200

RECEIVED
 APR 22 2001
 TECHNOLOGY CENTER R3700